Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity

被引：0
|
作者：
Jiawei Yue
Hui Guo
Peng Xu
Jinhong Ma
Weifeng Shi
Yumin Wu
机构：
[1] The Third Affiliated Hospital of Soochow University,Department of Orthopaedics
[2] The Third Affiliated Hospital of Soochow University,Department of Laboratory Medicine
[3] Institute of Nano and Soft Materials (FUNSOM) College of Nano Science &Technology (CNST) Suzhou,Jiangsu Key Laboratory for Carbon
来源：
Cancer Immunology, Immunotherapy | / 73卷
关键词：
Group 2 innate lymphoid cells; Interleukin-33; Cancer immunotherapy; Mature ILC2; Programmed cell death protein-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity
    Yue, Jiawei
    Guo, Hui
    Xu, Peng
    Ma, Jinhong
    Shi, Weifeng
    Wu, Yumin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (04)
  • [2] PD-1 blockade: promoting endogenous anti-tumor immunity
    Peggs, Karl S.
    Quezada, Sergio A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (10) : 1279 - 1282
  • [3] SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
    Zhao, M.
    Guo, W.
    Xu, Q.
    Sun, Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1856 - 1856
  • [4] SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
    Zhao, Mingxia
    Guo, Wenjie
    Wu, Yuanyuan
    Yang, Chenxi
    Zhong, Liang
    Deng, Guoliang
    Zhu, Yuyu
    Liu, Wen
    Gu, Yanhong
    Lu, Yin
    Kong, Lingdong
    Meng, Xiangbao
    Xu, Qiang
    Sun, Yang
    ACTA PHARMACEUTICA SINICA B, 2019, 9 (02) : 304 - 315
  • [5] SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
    Mingxia Zhao
    Wenjie Guo
    Yuanyuan Wu
    Chenxi Yang
    Liang Zhong
    Guoliang Deng
    Yuyu Zhu
    Wen Liu
    Yanhong Gu
    Yin Lu
    Lingdong Kong
    Xiangbao Meng
    Qiang Xu
    Yang Sun
    ActaPharmaceuticaSinicaB, 2019, 9 (02) : 304 - 315
  • [6] An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade
    Liu, Hongchuan
    Wang, Rui
    An, Duopeng
    Liu, Hui
    Ye, Fan
    Li, Baoxian
    Zhang, Jing
    Liu, Peixiang
    Zhang, Xuyao
    Yao, Sheng
    Zhong, Ziyang
    Feng, Hui
    Feng, Meiqing
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101
  • [7] GEN1046 (DuoBody®-PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity
    Capello, Michela
    Sette, Angelica
    Plantinga, Theo
    Spires, Vanessa
    Nuermberger, Kristina
    Blum, Jordan
    Muik, Alexander
    Sa, Carol Costa
    Jabado, Omar
    Burm, Saskia
    Toker, Aras
    Fellermeier-Kopf, Sina
    Ahmadi, Tahi
    Higgs, Brandon
    Couto, Suzana
    Tureci, Ozlem
    Fereshteh, Mark
    Sahin, Ugur
    Jure-Kunkel, Maria
    Pencheva, Nora
    CANCER RESEARCH, 2023, 83 (07)
  • [8] Pan-TGF-β inhibition with PD-1 blockade as a combination treatment strategy to augment anti-tumor immune response in hepatocellular carcinoma.
    Malkova, Natalia
    Theilhaber, Joachim
    Levit, Mikhail
    Tolstykh, Tatiana
    Hebert, Andrew
    Atchison, Kevin
    Maisonet, Adalis
    Sinicropi-Yao, Sara Sara
    Protopopov, Alexei
    Pollard, Jack
    Sidhu, Sukhvinder
    Lin, Tun Tun
    Pao, Lily
    Wiederschain, Dmitri
    Sharma, Sharad K.
    CANCER RESEARCH, 2021, 81 (13)
  • [9] PD-1 BLOCKADE ADMINISTERED BEFORE OR AT THE TIME OF T CELL ACTIVATION ENHANCES ANTI-TUMOR IMMUNITY
    Moseman, Jena
    McNeel, Douglas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A492 - A492
  • [10] Anti-tumor immunity evolved by novel titanium peroxide nanoparticles (TiOxNPs) as a radiosensitizer and PD-1 blockade
    Fujita, Yoshiko
    Kubota, Hikaru
    Ogino, Chiaki
    Sasaki, Ryohei
    CANCER RESEARCH, 2023, 83 (07)
12345